Monday, 31 August 2026European Markets

BSA CRE Stock Surges 20% In Five Sessions: Should Now Be The Time To Buy?

Loading stream...

(vianews) - pierre vac bsa cre (cac 40: vacbt.pa) experienced an incredible recovery over the last five sessions, increasing by 20% from eur0.35 to eur0.36 at 16:26 est on tuesday - this following five consecutive days of losses and two sessions of gains by this stock. pierre vac bsa cre closed its 52-week high price at eur0.35 but posted significant growth above this mark over this timeframe, ultimately reaching eur0.36 as its final closing price on tuesday at 16:26 est; its last closing price stood 2.27% above its 52-week high of eur0.35.

yearly analysis

based on available information, pierre vac bsa cre's stock is currently trading at eur0.36, exceeding its 52-week high of eur0.35 by 1 cent. this indicates that its performance over the past year has been positive and that a new high has been reached. investors need to conduct further analysis before making any definitive investment decisions, taking into account other factors like company financial performance, industry trends and market conditions before making their final investment decision. importantly, past results do not guarantee future returns and investing in the stock market always involves some level of risk. before making any investment decisions, investors should conduct thorough research and seek professional advice before taking action.

more news about pierre vac bsa cre (vacbt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com